Skip navigation

Refine by Type

Refine by Keyword

Results 1 - 10 of 20 for PAZOPANIB
  1. Pazopanib is used to treat advanced renal cell carcinoma (RCC, a type of cancer that begins in the cells of the kidneys) in adults. Pazopanib is in a class of medications called kinase ...
  2. Targeted Therapies for Kidney Cancer (American Cancer Society)  
    ... the intestines, heart problems, and slow wound healing. Pazopanib (Votrient ® ) Pazopanib is another drug that blocks several tyrosine kinases ...
  3. Targeted Cancer Therapies From the National Institutes of Health (National Cancer Institute)  
    ... VEGF signaling, thereby inhibiting angiogenesis and cell proliferation. Pazopanib (Votrient®) is approved to treat patients with advanced renal cell carcinoma and advanced soft tissue sarcoma . Pazopanib is a small-molecule inhibitor of several tyrosine ...
  4. ... in clinical trials include sorafenib (Nexavar ® ), sunitinib (Sutent ® ), pazopanib (Votrient ® ), cabozantinib (Cometriq), motesanib (AMG 706), axitinib (Inlyta ® ), ... Some other TKIs, such as sunitinib, sorafenib, and pazopanib, are already approved to treat other types of ...
  5. Cancer Drug Information From the National Institutes of Health (National Cancer Institute)  
    ... Hydrochloride Pamidronate Disodium Panitumumab Paraplat (Carboplatin) Paraplatin (Carboplatin) Pazopanib Hydrochloride Pegaspargase Peginterferon Alfa-2b PEG-Intron (Peginterferon ...
  6. Angiogenesis Inhibitors From the National Institutes of Health (National Cancer Institute)  
    ... have antiangiogenic activity, including sorafenib ( Nexavar ®), sunitinib ( Sutent ®), pazopanib ( Votrient ®), and everolimus ( Afinitor ®). Sorafenib is approved for ... for both kidney cancer and neuroendocrine tumors, and pazopanib for kidney cancer. Researchers are exploring the use ...
  7. Childhood Soft Tissue Sarcoma (PDQ): Treatment From the National Institutes of Health (National Cancer Institute)  
    ... is used in the treatment of dermatofibrosarcoma protuberans . Pazopanib is also a tyrosine kinase inhibitor used in ...
  8. ... as sorafenib (Nexavar ® ), nilotinib (Tasigna ® ), dasatinib (Sprycel ® ), and pazopanib (Votrient ™ ), are already being used to treat other ...
  9. ... against NPC, including bevacizumab (Avastin ® ), sorafenib (Nexavar ® ), and pazopanib (Votrient ® ). Immunotherapy NPC seems to be caused at ...
  10. ... or proteins, such as sorafenib (Nexavar), bevacizumab (Avastin), pazopanib (Votrient), and everolimus (Afinitor), are now being studied ...
previous · 1 · 2 · next